SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:56S1 • FR0013154002
191.6 EUR
-6.05 (-3.06%)
Last: Jan 29, 2026, 07:00 PM
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. While showing a medium growth rate, 56S1 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- In the past year 56S1 had a positive cash flow from operations.
- 56S1 had positive earnings in each of the past 5 years.
- Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
- 56S1's Return On Assets of 3.36% is on the low side compared to the rest of the industry. 56S1 is outperformed by 63.64% of its industry peers.
- 56S1's Return On Equity of 6.55% is in line compared to the rest of the industry. 56S1 outperforms 40.91% of its industry peers.
- 56S1 has a Return On Invested Capital (5.94%) which is comparable to the rest of the industry.
- The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.34%.
- The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.98%, 56S1 is in line with its industry, outperforming 54.55% of the companies in the same industry.
- 56S1's Profit Margin has declined in the last couple of years.
- 56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 63.64% of its industry peers.
- 56S1's Operating Margin has declined in the last couple of years.
- The Gross Margin of 56S1 (45.64%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- 56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
- The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
- The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 4.21 indicates that 56S1 is not in any danger for bankruptcy at the moment.
- 56S1 has a better Altman-Z score (4.21) than 77.27% of its industry peers.
- The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
- With a Debt to FCF ratio value of 6.84, 56S1 perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
- A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.50, 56S1 perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.21 |
ROIC/WACC0.61
WACC9.71%
2.3 Liquidity
- 56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of 56S1 (1.05) is worse than 72.73% of its industry peers.
- A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
- With a Quick ratio value of 0.50, 56S1 is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
- 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
- The Revenue has been growing slightly by 7.72% in the past year.
- Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
- 56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.86% yearly.
EPS Next Y29.12%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 44.45 indicates a quite expensive valuation of 56S1.
- Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 77.27% of the companies are valued more cheaply.
- The average S&P500 Price/Earnings ratio is at 28.39. 56S1 is valued rather expensively when compared to this.
- A Price/Forward Earnings ratio of 35.90 indicates a quite expensive valuation of 56S1.
- Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
- 56S1's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.45 | ||
| Fwd PE | 35.9 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
- 56S1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.78 | ||
| EV/EBITDA | 25.87 |
4.3 Compensation for Growth
- 56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as 56S1's earnings are expected to grow with 22.85% in the coming years.
PEG (NY)1.53
PEG (5Y)10.6
EPS Next 2Y23.48%
EPS Next 3Y22.85%
5. Dividend
5.1 Amount
- 56S1 has a yearly dividend return of 0.33%, which is pretty low.
- Compared to an average industry Dividend Yield of 0.48, 56S1 has a dividend in line with its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.82, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- 56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.37%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 44.45 and the Price/Book (PB) ratio is 4.62.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.12% in the next year.